Business Context and Reporting Period
This Form 8-K was filed by Henry Schein, Inc. on June 18, 2004, reporting a significant acquisition event. The company acquired demedis GmbH (excluding Austrian operations) and Euro Dental Holding GmbH, which includes DentalMV GmbH ("Muller & Weygandt") and KRUGG S.p.A. These entities are leading distributors of dental consumables and equipment in Germany, Austria, the Benelux countries, and Italy.
Key Financial Metrics
- Target Revenue: The combined companies (excluding Muller & Weygandt and Austrodent) recorded net sales of approximately EUR 285 million for the fiscal year ended September 30, 2003.
- Purchase Price: Approximately EUR 255 million, determined through arm's length negotiations.
- Debt Assumption: The purchase price includes the assumption and repayment of bank debt.
- Financing: Funded via cash on hand, borrowings under an existing revolving credit facility, and a $150 million bridge loan from JPMorgan Chase and Lehman Brothers, Inc.
Material Changes and Regulatory Conditions
Henry Schein plans to continue the acquired businesses as previously operated, subject to regulatory conditions. The company is required to divest Muller & Weygandt to satisfy German regulatory authorities, with the divestiture expected no later than July 31, 2004. The purchase price does not include proceeds from this divestiture. Additionally, regulatory authorities are continuing their review of the demedis business in Austria, which operates under the Austrodent brand.
Outlook and Management Commentary
Management intends to integrate the acquired entities while maintaining their existing operational models pending the completion of the required divestiture. The filing does not provide specific forward-looking financial guidance or updated earnings projections beyond the transaction details.
Investor Verification Checklist
- Confirm the final closing date and any adjustments to the EUR 255 million purchase price.
- Verify the timeline and buyer for the mandatory divestiture of Muller & Weygandt by July 31, 2004.
- Monitor the status of the regulatory review regarding the Austrodent operations in Austria.
- Assess the impact of the $150 million bridge loan and assumed debt on the company's liquidity and leverage ratios.